Dermira Inc (DERM)

Add to Watchlists
Create an Alert
13.62 -0.02  -0.15% NASDAQ Mar 21, 20:00 Delayed 2m USD
View Full Chart
DERM Price Chart
View All Events

DERM Events

Date Type Description
08/06/2019 Misc Dermira Inc Second Quarter Earnings Conference Call in 2019
05/03/2019 Earnings Dermira Inc First Quarter Earnings Results in 2019
02/26/2019 16:30 EST Misc Dermira Inc Fourth Quarter Earnings Conference Call in 2018
02/26/2019 Earnings Dermira Inc Fourth Quarter Earnings in 2018 Release
02/26/2019 Misc Dermira Inc Annual Report in 2018
11/07/2018 16:30 EST Misc Dermira Inc Third Quarter Earnings Conference Call in 2018
11/07/2018 Earnings Dermira Inc Third Quarter Earnings in 2018 Release
08/06/2018 Earnings Dermira Inc Second Quarter Earnings Results in 2018
08/06/2018 Misc Dermira Inc Second Quarter Earnings Conference Call in 2018
06/12/2018 Misc Dermira Inc Annual General Meeting in 2017
View All Performance Charts

DERM Total Returns Comparison

Advertisement

DERM One Page Reports

Edit

Profile

  • URL: http://www.dermira.com
  • Investor Relations URL: http://investor.dermira.com/phoenix.zhtml?c=253686&p=irol-irhome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: May. 03, 2019
  • Last Earnings Release: Feb. 26, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.

DERM Comparables

Edit

DERM Excel Add-In Codes

  • Name: =YCI("DERM","name")
  • Description: =YCI("DERM","description")
  • Sector: =YCI("DERM","sector")
  • Industry: =YCI("DERM","industry")
  • Est. Current Fiscal Year End: =YCI("DERM","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.